XOMA Royalty Corp
XOMAP
Company Profile
Business description
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.
Contact
2200 Powell Street
Suite 310
EmeryvilleCA94608
USAT: +1 510 204-7200
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
Employees
13
Stocks News & Analysis
stocks
This might be the best core stock bargain in the US market today
Patient investors should consider building a position in this wide-moat stock while it’s seriously undervalued.
stocks
Data center demand drives strong earnings outlook for SGM
Sims guides huge earnings upgrade as data center metals demand spikes.
stocks
Chart of the Week: AI proving a threat to company moats
The latest insights on AI from our equity research team.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,673.80 | 10.70 | 0.12% |
| CAC 40 | 7,807.87 | 162.01 | -2.03% |
| DAX 40 | 22,839.56 | 662.69 | -2.82% |
| Dow JONES (US) | 46,052.46 | 172.69 | -0.37% |
| FTSE 100 | 10,063.50 | 241.79 | -2.35% |
| HKSE | 25,388.99 | 111.59 | -0.44% |
| NASDAQ | 22,085.62 | 66.80 | -0.30% |
| Nikkei 225 | 53,372.53 | 1,866.87 | -3.38% |
| NZX 50 Index | 12,989.62 | 325.98 | -2.45% |
| S&P 500 | 6,606.30 | 18.40 | -0.28% |
| S&P/ASX 200 | 8,481.80 | 9.50 | 0.11% |
| SSE Composite Index | 4,003.03 | 3.52 | -0.09% |